Amyloid-β sequester proteins as blood-based biomarkers of cognitivedecline

Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

Volumn 1, Issue 2, 2015, Pages 270-280

  Uchida, Kazuhiko ^a   Shan, Liu ^a   Suzuki, Hideaki ^a,b   Tabuse, Yo ^a,b   Nishimura, Yoshinori ^a,b   Hirokawa, Yoshihiro ^c   Mizukami, Katsuyoshi ^a   Akatsu, Hiroyasu ^d   Meno, Kohji ^a,b   Asada, Takashi ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b Research Division MCBI Inc   (Japan)

^c Uji Hospital   (Japan)

^d Fukusimura Hospital   (Japan)

Author keywords

Alzheimer's disease; Apolipoprotein; Biomarker; Complement system; Diagnostics; Mild cognitive impairment; Transthyretin

Indexed keywords

EID: 84938687644     PISSN: None     EISSN: 23528729     Source Type: Journal    
DOI: 10.1016/j.dadm.2015.04.003     Document Type: Article

References (41)

1. Brookmeyer R., Johnson E., Ziegler-Graham K., Arrighi H.M. Forecasting the global burden of Alzheimer's disease. Alzheimers Dement 2007, 3:186-191.
2. Asada T. Report of Health and Labor Sciences Research Grants (201218011A) 2013, Tokyo.
3. Leow A.D., Yanovsky I., Parikshak N., Hua X., Lee S., Toga A.W., et al. Alzheimer's disease neuroimaging initiative: a one-year follow up study using tensor-based morphometry correlating degenerative rates, biomarkers and cognition. Neuroimage 2009, 45:645-655.
4. Alzheimer's Association Report: 2014 Alzheimer's disease facts and figures. Alzheimers Dement 2014, 10:e47-e92. Alzheimer's Association.
5. Petersen R.C., Smith G.E., Waring S.C., Ivnik R.J., Tangalos E.G., Kokmen E. Mild cognitive impairment: Clinical characterization and outcome. Arch Neurol 1999, 56:303-308.
6. Lacor P.N., Buniel M.C., Furlow P.W., Clemente A.S., Velasco P.T., Wood M., et al. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci 2007, 27:796-807.
7. Lesne S., Koh M.T., Kotilinek L., Kayed R., Glabe C.G., Yang A., et al. A specific amyloid-β protein assembly in the brain impairs memory. Nature 2006, 440:352-357.
8. Aiyaz M., Lupton M.K., Proitsi P., Powell J.F., Lovestone S. Complement activation as a biomarker for Alzheimer's disease. Immunobiology 2012, 217:204-215.
9. Strohmeyer R., Ramirez M., Cole G.J., Mueller K., Rogers J. Association of factor H of the alternative pathway of complement with agrin and complement receptor 3 in the Alzheimer's disease brain. J Neuroimmunol 2002, 131:135-146.
10. Chang C.Y., Lee Y.H., Leu S.J., Wang C.Y., Wei C.P., Hung K.S., et al. CC-chemokine ligand 18/pulmonary activation-regulated chemokine expression in the CNS with special reference to traumatic brain injuries and neoplastic disorders. Neuroscience 2010, 165:1233-1243.
11. Qiu Z., Strickland D.K., Hyman B.T., Rebeck G.W. α2-macroglobulin enhances the clearance of endogenous soluble β-amyloid peptide via low-density lipoprotein receptor-related protein in cortical neurons. JNeurochem 1999, 73:1393-1398.
12. Lee C.Y., Tse W., Smith J.D., Landreth G.E. Apolipoprotein E promotes β-amyloid trafficking and degradation by modulating microglial cholesterol levels. J Biol Chem 2012, 287:2032-2044.
13. Paula-Lima A.C., Tricerri M.A., Brito-Moreira J., Bomfim T.R., Oliveira F.F., Magdesian M.H., et al. Human apolipoprotein A-I binds amyloid-β and prevents Aβ-induced neurotoxicity. Int J Biochem Cell Biol 2009, 41:1361-1370.
14. Yu J.T., Tan L. The role of clusterin in Alzheimer's disease: Pathways, pathogenesis, and therapy. Mol Neurobiol 2012, 45:314-326.
15. Schwarzman A.L., Gregori L., Vitek M.P., Lyubski S., Strittmatter W.J., Enghilde J.J., et al. Transthyretin sequesters amyloid β protein and prevents amyloid formation. Proc Natl Acad Sci U S A 1994, 91:8368-8372.
16. Buxbaum J.N., Ye Z., Reixach N., Friske L., Levy C., Das P., et al. Transthyretin protects Alzheimer's mice from the behavioral and biochemical effects of Aβ toxicity. Proc Natl Acad Sci U S A 2008, 105:2681-2686.
17. Miyamoto M., Kodama C., Kinoshita T., Yamashita F., Hidaka S., Mizukami K., et al. Dementia and mild cognitive impairment among non-responders to a community survey. J Clin Neurosci 2009, 16:270-276.
18. Matsuda H., Mizumura S., Nagao T., Ota T., Iizuka T., Nemoto K., et al. An easy Z-score imaging system for discrimination between very early Alzheimer's disease and controls using brain perfusion SPECT in a multicentre study. Nucl Med Commun 2007, 28:199-205.
19. Matsuda H., Mizumura S., Nemoto K., Yamashita F., Imabayashi E., Sato N., et al. Automatic voxel-based morphometry of structural MRI by SPM8 plus diffeomorphic anatomic registration through exponentiated lie algebra improves the diagnosis of probable Alzheimer Disease. AJNR Am J Neuroradiol 2012, 33:1109-1114.
20. Yesavage J.A., Brink T.L., Rose T.L., Lum O., Huang V., Adey M., et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 1982, 17:37-49.
21. Jack C.R., Knopman D.S., Jagust W.J., Shaw L.M., Aisen P.S., Weiner M.W., et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010, 9:119-128.
22. Biessels G.J., Staekenborg S., Brunner E., Brayne C., Scheltens P. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol 2006, 5:64-74.
23. Ott A., Stolk R.P., van Harskamp F., Pols H.A., Hofman A., Breteler M.M. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 1999, 53:1937-1942.
24. Jaeger S., Pietrzik C.U. Functional role of lipoprotein receptors in Alzheimer's disease. Curr Alzheimer Res 2008, 5:15-25.
25. Castano E.M., Roher A.E., Esh C.L., Kokjohn T.A., Beach T. Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer's disease and non-demented elderly subjects. Neurol Res 2006, 28:155-163.
26. Roher A.E., Maarouf C.L., Sue L.I., Hu Y., Wilson J., Beach T.G. Proteomics-derived cerebrospinal fluid markers of autopsy-confirmed Alzheimer's disease. Biomarkers 2009, 14:493-501.
27. Bertram L., McQueen M.B., Mullin K., Blacker D., Tanzi R.E. Systematic meta-analyses of Alzheimer disease genetic association studies: The AlzGene database. Nat Genet 2007, 39:17-23.
28. Scacchi R., Gambina G., Ruggeri M., Martini M.C., Ferrari G., Silvestri M., et al. Plasma levels of apolipoprotein E and genetic markers in elderly patients with Alzheimer's disease. Neurosci Lett 1999, 259:33-36.
29. Slooter A.J., de Knijff P., Hofman A., Cruts M., Breteler M.M., Van Broeckhoven C., et al. Serum apolipoprotein E level is not increased in Alzheimer's disease: The Rotterdam study. Neurosci Lett 1998, 248:21-24.
30. DeMattos R.B., Cirrito J.R., Parsadanian M., May P.C., O'Dell M.A., Taylor J.W., et al. ApoE and clusterin cooperatively suppress Aβ levels and deposition: Evidence that ApoE regulates extracellular Aβ metabolism invivo. Neuron 2004, 41:193-202.
31. IJsselstijn L., Dekker L.J., Koudstaal P.J., Hofman A., Sillevis Smitt P.A., Breteler M.M., et al. Serum clusterin levels are not increased in presymptomatic Alzheimer's disease. J Proteome Res 2011, 10:2006-2010.
32. Thambisetty M., Simmons A., Velayudhan L., Hye A., Campbell J., Zhang Y., et al. Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch Gen Psychiatry 2010, 67:739-748.
33. Bonifati D.M., Kishore U. Role of complement in neurodegeneration and neuroinflammation. Mol Immunol 2007, 44:999-1010.
34. Veerhuis R., Nielsen H.M., Tenner A.J. Complement in the brain. Mol Immunol 2011, 48:1592-1603.
35. Sousa J.C., Cardoso I., Marques F., Saraiva M.J., Palha J.A. Transthyretin and Alzheimer's disease: Where in the brain?. Neurobiol Aging 2007, 28:713-718.
36. Biroccio A., Del Boccio P., Panella M., Bernardini S., Di Ilio C., Gambi D., et al. Differential post-translational modifications of transthyretin in Alzheimer's disease: A study of the cerebral spinal fluid. Proteomics 2006, 6:2305-2313.
37. Gloeckner S.F., Meyne F., Wagner F., Heinemann U., Krasnianski A., Meissner B., et al. Quantitative analysis of transthyretin, tau and amyloid-β in patients with dementia. J Alzheimers Dis 2008, 14:17-25.
38. Han S.H., Jung E.S., Sohn J.H., Hong H.J., Hong H.S., Kim J.W., et al. Human serum transthyretin levels correlate inversely with Alzheimer's disease. J Alzheimers Dis 2011, 25:77-84.
39. Velayudhan L., Killick R., Hye A., Kinsey A., Guntert A., Lynham S., et al. Plasma transthyretin as a candidate marker for Alzheimer's disease. JAlzheimers Dis 2012, 28:369-375.
40. Milojevic J., Raditsis A., Melacini G. Human serum albumin inhibits Aβ fibrillization through a "monomer-competitor" mechanism. Biophys J 2009, 97:2585-2594.
41. Stanyon H.F., Viles J.H. Human serum albumin can regulate amyloid-β peptide fiber growth in the brain interstitium: Implications for Alzheimer disease. J Biol Chem 2012, 287:28163-28168.